Biopharmaceutical Manufacturing Using Blow–Fill–Seal Technology - The authors give special consideration factors affecting blow–fill–seal technology. - BioPharm International


Biopharmaceutical Manufacturing Using Blow–Fill–Seal Technology
The authors give special consideration factors affecting blow–fill–seal technology.

BioPharm International
Volume 24, Issue 7, pp. 22-29


A biological manufacturing validation program encompasses equipment qualification, cleaning validation, and process validation. The BFS equipment suppliers and manufacturers usually have well-established practices for performing equipment qualification and cleaning validation. Process validation, however, could be a challenge for biological manufacturing using BFS technology.

The goal of process validation is to provide a high degree of assurance that the specific manufacturing process will consistently produce product meeting predetermined acceptance criteria. Modern-day process validation programs consist of process characterization studies and full-scale qualification lots produced under GMP conditions. Process characterization can be performed on each unit operation to evaluate and characterize an acceptable range of operating conditions that yields acceptable product quality and process performance. A quality-by-design (QbD) approach, which systematically uses risk assessments and multivariate characterization studies, is the current state of the art. Process characterization may be carried out at different scales, and it may also include engineering runs to mimic the overall process flow. Based on the outcome of process characterization, full scale GMP batches are manufactured under normal settings. Both physical attributes (such as ampul appearance, integrity, fill volume, and wall thickness) and chemical attributes of the product are checked to ensure that the process performs as expected.

It is important to recognize the uniqueness of the BFS process when applying the above process characterization and process-validation approach. The BFS machine is a custom-built machine. The equipment setup and operation often involves both automation control and manual adjustments. The operator experience or "know how" generally is very important to the proper operation of the BFS equipment. Such operator-dependent performance, to a certain extent, is in contrast to the QbD paradigm of pharmaceutical manufacturing, where critical process parameters (CPPs) are identified, understood, controlled, and monitored to achieve a robust manufacturing process. The large number of controllable and uncontrollable parameters in the BFS process makes process characterization and process validation much more challenging than conventional biological filling processes. For instance, the filling speed for a peristaltic or rotary piston pump is the typical process parameter that can be evaluated during stand-alone process-characterization studies. The filling speed, however, for a BFS process is mostly fixed, due to constraints from synchronized movement of the extruder, mold, filling, and seal operations. Only minor adjustments can be made to the duration of each of the BFS steps (extruding, molding, and filling), and such adjustment may be necessary to achieve optimum product appearance.

Another example of manually adjusted parameters is the plastic-resin weight. The resin weight determines how much plastic is extruded to form the container and directly correlates with the container wall thickness. Too much resin may result in containers with "bulky" appearance or problems with deflash while too little resin may cause issues for container integrity or ampoule leakage. The appropriate amount (or range) of resin is typically determined from equipment qualification. It can only be manually adjusted through a few mechanical parts at the beginning of each product run. Therefore, the process and product development for BFS process needs to balance an empirical approach and a systematic approach. The biological manufacturer needs to collaborate closely with the BFS equipment supplier or contract manufacturer to design a robust program for process characterization and validation.

Figure 4: Process flow for blow–fill–seal (BFS) process characterization and validation (CPP is critical process parameter; PC is process characterization).
Figure 4 provides an example of the potential roadmap for process characterization and process validation. Risk assessments are highly recommended for each unit operation as well as for each of the steps from the BFS operation in order to identify potential failure modes from equipment and mechanics, as well as product-impact aspects. The output from the risk assessments would be a list of process parameters that could affect the overall process or product quality. Further development and characterization studies should be designed for these parameters either as stand-alone studies or overall engineering runs. CPPs are selected based on the outcome of process characterization. Finally, full-scale qualification lots should be produced (typically at target settings of the process parameters) to demonstrate the validated state of the end-to-end process.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International,
Click here